Conditions: Stage IIIB or IV Non-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 253
Healthy volunteers: no

Brief summary:
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin

Detailed description:

Arms:
arm 1: vorinostat; IV paclitaxel; IV carboplatin arm 2: Placebo; IV paclitaxel; IV carboplatin

Interventions: intervention 1: vorinostat intervention 2: Comparator: paclitaxel intervention 3: Comparator: carboplatin intervention 4: Comparator: placebo
Intervention descriptions: intervention 1: vorinostat 400 mg capsules once daily. Up to 6 months of treatment intervention 2: intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment intervention 3: intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment. intervention 4: vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment

Protocol document: